DE69528624T2 - Anti-Fas Antikörper gegen rheumatische Krankheiten - Google Patents

Anti-Fas Antikörper gegen rheumatische Krankheiten

Info

Publication number
DE69528624T2
DE69528624T2 DE69528624T DE69528624T DE69528624T2 DE 69528624 T2 DE69528624 T2 DE 69528624T2 DE 69528624 T DE69528624 T DE 69528624T DE 69528624 T DE69528624 T DE 69528624T DE 69528624 T2 DE69528624 T2 DE 69528624T2
Authority
DE
Germany
Prior art keywords
fas
monoclonal antibody
antibodies against
rheumatic diseases
fas antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69528624T
Other languages
English (en)
Other versions
DE69528624D1 (de
Inventor
Kusiki Nishioka
Shin Yoneyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69528624D1 publication Critical patent/DE69528624D1/de
Publication of DE69528624T2 publication Critical patent/DE69528624T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69528624T 1994-09-27 1995-09-27 Anti-Fas Antikörper gegen rheumatische Krankheiten Expired - Lifetime DE69528624T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27013494 1994-09-27

Publications (2)

Publication Number Publication Date
DE69528624D1 DE69528624D1 (de) 2002-11-28
DE69528624T2 true DE69528624T2 (de) 2003-06-26

Family

ID=17482032

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69528624T Expired - Lifetime DE69528624T2 (de) 1994-09-27 1995-09-27 Anti-Fas Antikörper gegen rheumatische Krankheiten

Country Status (9)

Country Link
US (1) US6086877A (de)
EP (1) EP0709097B1 (de)
KR (1) KR100371000B1 (de)
AT (1) ATE226447T1 (de)
CA (1) CA2158822C (de)
DE (1) DE69528624T2 (de)
DK (1) DK0709097T3 (de)
ES (1) ES2182860T3 (de)
PT (1) PT709097E (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
IL123756A0 (en) * 1997-03-21 1998-10-30 Sankyo Co Humanized anti-human FAS antibody
DE69938451T2 (de) 1998-06-18 2009-04-09 Imed Ab Fas peptide und antikörper zur modulierung von apoptosis
CZ20014181A3 (cs) * 1999-05-24 2002-03-13 Sankyo Company Limited Farmaceutický prostředek obsahující protilátku a pouľití protilátky
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
AU2002210926B2 (en) 2000-10-24 2005-12-15 Shunichi Shiozawa Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis
US20060104951A1 (en) * 2004-11-16 2006-05-18 Mountz John D Akt and regulation of RA synovial fibroblast apoptosis
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
EP2322220B1 (de) * 2008-08-01 2014-01-01 Axis, Inc. Therapeutikum bzw. prophylaktikum für osteoarthritis
EP2529751A4 (de) * 2010-01-29 2013-07-31 Axis Inc Injizierbare lösung mit einem mittel zur behandlung von osteoarthritis
KR20120115383A (ko) * 2010-01-29 2012-10-17 가부시키가이샤 아크시스 변형성 관절증 치료 또는 예방용 의약 조성물 및 이의 제조 방법
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
BR112014017229B1 (pt) 2012-01-12 2022-05-17 Auxilium International Holdings, Inc Ácido nucleico recombinante, cassette de expressão, vetor, célula hospedeira recombinante, método de produção da colagenase i ou ii, colagenase i ou ii, composição farmacêutica, e método de produção de um produto de droga
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
US11123280B2 (en) 2017-03-01 2021-09-21 Endo Ventures Limited Method of assessing and treating cellulite
EP3601556A2 (de) 2017-03-28 2020-02-05 Endo Ventures Limited Verbessertes verfahren zur herstellung von collagenase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201712A (ja) * 1982-05-18 1983-11-24 Green Cross Corp:The 脂肪乳剤
JPS6051105A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The プロスタグランジン脂肪乳剤
JPH02237935A (ja) * 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
WO1991010448A1 (en) * 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
DE69233441T2 (de) * 1991-04-26 2005-10-13 Osaka Bioscience Institute, Suita Menschliches Zelloberflächen-Antigen codierende DNA
EP0603194A4 (de) * 1991-07-05 1994-12-07 Seragen Inc Zum rezeptor des epidermalen wachstumsfaktors zielgesteuerte moleküle zur behandlung entzündlicher arthritis.
EP0623598A4 (de) * 1992-08-19 1997-05-02 Otsuka Pharma Co Ltd Apoptose regulatoren.
US5830469A (en) * 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
KR960704938A (ko) * 1993-10-14 1996-10-09 그리스토퍼 엘. 와이트 Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)

Also Published As

Publication number Publication date
EP0709097A1 (de) 1996-05-01
PT709097E (pt) 2003-03-31
KR960010024A (ko) 1996-04-20
US6086877A (en) 2000-07-11
ES2182860T3 (es) 2003-03-16
KR100371000B1 (ko) 2003-07-12
CA2158822C (en) 2008-12-23
EP0709097B1 (de) 2002-10-23
CA2158822A1 (en) 1996-03-28
DE69528624D1 (de) 2002-11-28
DK0709097T3 (da) 2003-02-24
ATE226447T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
DE69528624D1 (de) Anti-Fas Antikörper gegen rheumatische Krankheiten
Verneuil et al. Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies
Rock et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem)
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
BR0213846A (pt) métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
BR0314038A (pt) Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado
LU91556I2 (fr) Anticorps humains reconstitués dirigés contre un récepteur de l'interleukine 6 humaine - TOCILIZUMAB
BR0317376A (pt) Anticorpo humanizado (h14.18) do anticorpo 14.18 do camundongo que se liga a gd2 e sua fusão com il-2
AU2002211366A1 (en) Human anti-cd40 antibodies
NO20001238D0 (no) Monoklonalt antistoff som induserer apoptose
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
ATE159300T1 (de) Monoklonale antikörper gegen menschliches ige
WO2003054018A3 (en) Anti-tirc7 antibodies in therapy of inflammatory diseases
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
Patterson-Fortin et al. Serum sickness-like reaction after the treatment of cellulitis with amoxicillin/clavulanate
BR0116010A (pt) Kit imunoterapêutico para o tratamento de tumores
Duzova et al. An unusual pattern of arthritis in a child with Kawasaki syndrome
WO2005058358A3 (en) Use of agents derived from ceacam1 for the treatment of inflammatory diseases
Jha et al. Two cases of adult-onset de novo immunoglobulin A vasculitis with nephritis: post-Covishield (ChAdOx1 nCoV-19; Oxford–Astra Zeneca) vaccination
Cavallasca et al. Multiple avascular necrosis in a patient with systemic lupus erythematosus/systemic sclerosis overlap syndrome
Wakabayashi et al. Long-Term Maintenance of Golimumab Effectiveness for Injection Spacing in Rheumatoid Arthritis Patients with Low Disease Activity Who Previously Received Other TNF Inhibitors: Minimum 2-year Data From an Observational Study
Nallegowda et al. An unusual nail presentation in Marfan's syndrome

Legal Events

Date Code Title Description
8364 No opposition during term of opposition